<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Rheumatol Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">Rheumatol Immunol Res</journal-id><journal-id journal-id-type="publisher-id">rir</journal-id><journal-id journal-id-type="doi">rir</journal-id><journal-title-group><journal-title>Rheumatology and Immunology Research</journal-title></journal-title-group><issn pub-type="epub">2719-4523</issn><publisher><publisher-name>De Gruyter</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10729589</article-id><article-id pub-id-type="publisher-id">rir-2023-0033</article-id><article-id pub-id-type="doi">10.2478/rir-2023-0033</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Overcoming rheumatoid arthritis challenges: Ensuring timely referral to rheumatologists in resource-scarce countries</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8430-9299</contrib-id><name><surname>Khan</surname><given-names>Anum</given-names><prefix>Dr.</prefix></name><email xlink:href="mailto:dranumkhan66@gmail.com">dranumkhan66@gmail.com</email><xref rid="j_rir-2023-0033_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Salim</surname><given-names>Babur</given-names></name><xref rid="j_rir-2023-0033_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Perveen</surname><given-names>Shahida</given-names></name><xref rid="j_rir-2023-0033_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Samreen</surname><given-names>Saba</given-names></name><xref rid="j_rir-2023-0033_aff_002" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Gul</surname><given-names>Haris</given-names></name><xref rid="j_rir-2023-0033_aff_001" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Nasim</surname><given-names>Amjad</given-names></name><xref rid="j_rir-2023-0033_aff_001" ref-type="aff"/></contrib><aff id="j_rir-2023-0033_aff_001"><institution>Rheumatology Department, Fauji Foundation Hospital</institution>, <city>Rawalpindi</city>, <country country="PK">Pakistan</country></aff><aff id="j_rir-2023-0033_aff_002"><institution>Foundation University School of Health Sciences (FUSH)</institution>, <city>Rawalpindi</city>, <country country="PK">Pakistan</country></aff></contrib-group><author-notes><corresp><sup>*</sup>Dr. Anum Khan, Rheumatology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>12</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2023</year></pub-date><volume>4</volume><issue>4</issue><fpage>222</fpage><lpage>224</lpage><history><date date-type="received"><day>23</day><month>7</month><year>2023</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 Anum Khan, Babur Salim, Shahida Perveen, Saba Samreen, Haris Gul, Amjad Nasim, published by De Gruyter on behalf of NCRC-DID</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Anum Khan, Babur Salim, Shahida Perveen, Saba Samreen, Haris Gul, Amjad Nasim, published by De Gruyter on behalf of NCRC-DID</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under the Creative Commons Attribution 4.0 International License.</license-p></license></permissions><funding-group><funding-statement>
<italic toggle="yes">None</italic>
</funding-statement></funding-group><counts><page-count count="3"/></counts></article-meta></front><body><p>Dear Editor,</p><p>Rheumatoid arthritis (RA) is one of the most common autoimmune inflammatory diseases with an estimated prevalence of 0.5%&#x02013;1%.<sup>[<xref rid="j_rir-2023-0033_ref_001" ref-type="bibr">1</xref>]</sup> Inflammation of the synovium is the hallmark of this disease, which can cause destruction and deformities of joints if left uncontrolled. Around 70% of the radiographic damage and deformities occur within the first two years of its onset, leading to permanent disability.<sup>[<xref rid="j_rir-2023-0033_ref_002" ref-type="bibr">2</xref>]</sup> Delaying treatment for more than a year has a significant association with radiographic damage.<sup>[<xref rid="j_rir-2023-0033_ref_003" ref-type="bibr">3</xref>]</sup></p><p>Early diagnosis and treatment are the essence of management of RA.<sup>[<xref rid="j_rir-2023-0033_ref_004" ref-type="bibr">4</xref>,<xref rid="j_rir-2023-0033_ref_005" ref-type="bibr">5</xref>]</sup> Timely management increases the odds of a favorable outcome in RA patients by preserving functionality and reducing morbidity.</p><p>Local data of Pakistan depicts a mean delay in diagnosis of rheumatoid arthritis by 1 year, and therapeutic delay of 1.5 year.<sup>[<xref rid="j_rir-2023-0033_ref_004" ref-type="bibr">4</xref>]</sup> Rheumatologists believe that there is a &#x0201c;window of opportunity&#x0201d; for treating RA, that is early in the disease, which if availed results in a better prognosis and quality of life.<sup>[<xref rid="j_rir-2023-0033_ref_006" ref-type="bibr">6</xref>]</sup> Multiple factors are attributable to the diagnostic and therapeutic delay and losing the window of opportunity, such as lack of awareness and resources, diagnostic ambiguity in some cases of early RA and difficult access to a rheumatologist.</p><p>Considering the diagnostic and therapeutic difficulties, recent guidelines endorse that rheumatologists should treat patients with RA.<sup>[<xref rid="j_rir-2023-0033_ref_005" ref-type="bibr">5</xref>]</sup> This is hard to implement, as the prevalence of rheumatoid arthritis is 1% of the world&#x02019;s population,<sup>[<xref rid="j_rir-2023-0033_ref_007" ref-type="bibr">7</xref>]</sup> and 0.55% of Pakistan&#x02019;s population (1.15 million people in 2023)<sup>[<xref rid="j_rir-2023-0033_ref_004" ref-type="bibr">4</xref>]</sup> Against this burden of disease, the number of rheumatologists in Pakistan is limited, around 100 registered with Pakistan society of Rheumatology (PSR). These hurdles can be overcome by close collaboration of rheumatologists with other clinicians.</p><p>We are proposing a simple algorithm for general physicians to help them in diagnosis and management of early RA and when to refer a patient to a rheumatologist. The algorithm was created through consensus and voting of rheumatolo-gists in various cities of Pakistan. The selected items were finalized after a survey carried out among the general physicians during the project &#x0201c;Rheumatoid Arthritis Awareness Among Local General Physicians (GPs) of Pakistan: From Diagnosis to Referral&#x0201d; carried out by rheumatology department Fauji Foundation Hospital, funded by the International League of Associations for Rheumatology (ILAR) in 2023. This can refine the referral system and is easily applicable worldwide especially in countries where limited number of rheumatologists are available. The rationale of this referral is to diagnose and initiate early treatment. It should be noted that imaging has not been mentioned in this algorithm as it is a specialized tool used specifically by rheumatologists or radiologists (<xref rid="j_rir-2023-0033_fig_001" ref-type="fig">Figure 1</xref>). General physicians should know the following facts before referring an RA patient to a rheumatologist.</p><fig position="float" id="j_rir-2023-0033_fig_001" fig-type="figure"><label>Figure 1</label><caption><p>Rationale: Earlier initiation of optimal treatment. *Hypersensitivity, impaired liver function, pregnancy, breast-feeding, alcohol use, immunodeficiency syndromes, blood dyscrasias, severe renal impairment. CBC: complete blood count; LFTs: liver function tests.</p></caption><graphic xlink:href="j_rir-2023-0033_fig_001" position="float"/></fig><sec id="j_rir-2023-0033_s_001"><title>Picking arthritis/synovitis</title><p>Learn to pick arthritis/synovitis with history (joint swelling, pain, significant stiffness for at least an hour) and clinical examination (joint swelling, tenderness, limited range of motion). Rule out other causes of synovitis and polyarthritis on the basis of clinical history and examination, like viral (duration &#x0003c; 6 weeks), psoriasis (own or family history of skin or nail disease), systemic lupus erythematosus (presence of oral/nasal ulcers, alopecia, photosensitivity, rash, Raynaud&#x02019;s phenomenon, muscle weakness/pain), crystal arthritis and nodal/erosive osteoarthritis <italic toggle="yes">etc</italic>. If there is suspicion of an alternate diagnosis, consider referral to a rheumatologist (<xref rid="j_rir-2023-0033_fig_002" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="j_rir-2023-0033_fig_002" fig-type="figure"><label>Figure 2</label><caption><p>Approach for atypical cases. RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibody; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.</p></caption><graphic xlink:href="j_rir-2023-0033_fig_002" position="float"/></fig></sec><sec id="j_rir-2023-0033_s_002"><title>Interpretation of laboratory tests</title><p>Laboratory tests like rheumatoid factor (RF), anti-cyclic citrul-linated peptide antibodies (anti-CCP), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) can aid in diagnosing RA. Some laboratories in the peripheries don&#x02019;t have the facility for testing anti-CCP and CRP, so either one of raised ESR or CRP, and RF or anti-CCP positivity can suffice. The diagnosis of rheumatoid arthritis is always clinical and never solely based on the positivity of tests. Around 70% of RA patients are RF and/or anti-CCP antibodies (seroposi-tive).<sup>[<xref rid="j_rir-2023-0033_ref_008" ref-type="bibr">8</xref>]</sup> In the presence of clinical features of RA and negative antibodies, it is called &#x02018;seronegative RA&#x02019;. Acute phase reactants (ESR and CRP) are non-specific and can be normal in up to 30% of patients with active rheumatoid arthritis.<sup>[<xref rid="j_rir-2023-0033_ref_009" ref-type="bibr">9</xref>]</sup> Therefore, interpret the tests judiciously.</p></sec><sec id="j_rir-2023-0033_s_003"><title>Base line tests prior to initiation of standard treatment</title><p>When the diagnosis of RA is established, it is essential to obtain complete blood count, liver function tests and serum creatinine before the initiation of disease modifying agent.</p></sec><sec id="j_rir-2023-0033_s_004"><title>Treatment</title><p>After confirming the diagnosis of RA, initiate treatment promptly with a conventional synthetic disease modifying anti-rheumatic drug (csDMARD). Methotrexate is the first line treatment drug unless there is any contraindication.<sup>[<xref rid="j_rir-2023-0033_ref_002" ref-type="bibr">2</xref>,<xref rid="j_rir-2023-0033_ref_005" ref-type="bibr">5</xref>]</sup> Initiate at a dose of 7.5&#x02013;15 mg/week and titrate dose up to 20&#x02013;25 mg/week within 4&#x02013;6 weeks after checking complete blood count (CBC), serum alanine transaminase (ALT) and creatinine. Folic acid must be co-prescribed with methotrexate to avoid its side effects (at least 5 mg/week). Consider oral short-term low-dose steroids (&#x02264;7.5 mg/day prednisone equivalent for about 3 months)<sup>[<xref rid="j_rir-2023-0033_ref_005" ref-type="bibr">5</xref>]</sup> as bridging therapy while the csDMARD takes effect.</p></sec><sec id="j_rir-2023-0033_s_005"><title>When to refer to a rheumatologist?</title><p>Ideally, rheumatologists are the primary physicians to treat RA patients, and the earlier the referral, the better the outcome. However, if the rheumatologist is not easily available or patient cannot reach the rheumatologist in time, start methotrex-ate (if there is no contraindication) considering early initiation of disease modifying drug can prevent irreversible damage. (1) Diagnosis is uncertain; (2) Severe or rapidly progressing disease; (3) Poor response to initial treatment within 3&#x02013;4 months; (4) Life-threatening or organ-threatening extra-articular manifestations of RA (like vasculitis); (5) Pregnancy or fertility issues; (6) Need for biologic or targeted synthetic DMARD therapy.</p></sec><sec id="j_rir-2023-0033_s_006"><title>Follow up</title><p>We suggest to regularly monitor patient&#x02019;s disease activity, response to treatment and any potential adverse effects, and collaborate with rheumatologist for long-term management plan.</p></sec></body><back><ack id="j_rir-2023-0033_ack_007"><title>Acknowledgement</title><p><italic toggle="yes">None</italic>.</p></ack><fn-group><fn fn-type="con" id="j_rir-2023-0033_fn_101"><p>
<bold>Author Contributions</bold>
</p><p><italic toggle="yes">Anum Khan: Conceptualization, writing, original draft preparation; Babur Salim: Conceptualization, Writing; Shahida Perveen: Reviewing and editing; Saba Samreen: Reviewing, Supervision; Haris Gul: Reviewing and editing; Amjad Nasim: Project administration</italic>.</p></fn><fn fn-type="other" id="j_rir-2023-0033_fn_105"><p>
<bold>Informed Consent</bold>
</p><p><italic toggle="yes">Informed verbal consent was obtained from participants for research and publication</italic>.</p></fn><fn fn-type="other" id="j_rir-2023-0033_fn_103"><p>
<bold>Ethical Approval</bold>
</p><p><italic toggle="yes">Not applicable</italic>.</p></fn><fn fn-type="COI-statement" id="j_rir-2023-0033_fn_102"><p>
<bold>Conflict of Interest</bold>
</p><p><italic toggle="yes">The authors declare no competing interest</italic>.</p></fn><fn fn-type="other" id="j_rir-2023-0033_fn_106"><p>
<bold>Data Availability Statement</bold>
</p><p><italic toggle="yes">No additional data</italic>.</p></fn></fn-group><ref-list><title>References</title><ref id="j_rir-2023-0033_ref_001"><label>[1]</label><element-citation publication-type="journal"><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Breedveld</surname><given-names>FC</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide</article-title><source>Ann Rheum Dis</source><year>2002</year><volume>61</volume><fpage>290</fpage><comment>&#x02013;</comment><lpage>297</lpage><pub-id pub-id-type="pmid">11874828</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_002"><label>[2]</label><element-citation publication-type="journal"><name><surname>Fraenkel</surname><given-names>L</given-names></name><name><surname>Bathon</surname><given-names>JM</given-names></name><name><surname>England</surname><given-names>BR</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><year>2021</year><article-title>American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis</article-title><source>Arthritis Rheumatol</source><comment>2021</comment><volume>73</volume><fpage>1108</fpage><comment>&#x02013;</comment><lpage>1123</lpage><pub-id pub-id-type="pmid">34101376</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_003"><label>[3]</label><element-citation publication-type="journal"><name><surname>Rosa</surname><given-names>JE</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>MV</given-names></name><name><surname>Luissi</surname><given-names>A</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Rheumatoid Arthritis Patient&#x02019;s Journey: Delay in Diagnosis and Treatment</article-title><source>J Clin Rheu-matol</source><year>2020</year><volume>26</volume><fpage>S148</fpage><comment>-</comment><lpage>S152</lpage></element-citation></ref><ref id="j_rir-2023-0033_ref_004"><label>[4]</label><element-citation publication-type="journal"><name><surname>Naeem</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>SEA</given-names></name><name><surname>Saeed</surname><given-names>MA</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>Diagnostic and therapeutic delay in Rheumatoid Arthritis patients: Impact on disease outcome</article-title><source>Pak J Med Sci</source><year>2021</year><volume>37</volume><fpage>1001</fpage><comment>&#x02013;</comment><lpage>1007</lpage><pub-id pub-id-type="pmid">34290773</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_005"><label>[5]</label><element-citation publication-type="journal"><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Landew&#x000e9;</surname><given-names>RBM</given-names></name><name><surname>Bergstra</surname><given-names>SA</given-names></name><comment>
<italic toggle="yes">et al</italic>
</comment><article-title>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update</article-title><source>Ann Rheum Dis</source><year>2023</year><volume>82</volume><fpage>3</fpage><comment>&#x02013;</comment><lpage>18</lpage><pub-id pub-id-type="pmid">36357155</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_006"><label>[6]</label><element-citation publication-type="journal"><name><surname>Cush</surname><given-names>JJ</given-names></name><article-title>Rheumatoid Arthritis: Early Diagnosis and Treatment</article-title><source>Rheum Dis Clin North Am</source><year>2022</year><volume>48</volume><fpage>537</fpage><comment>-</comment><lpage>547</lpage><pub-id pub-id-type="pmid">35400377</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_007"><label>[7]</label><element-citation publication-type="journal"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Nossent</surname><given-names>J</given-names></name><name><surname>Pavlos</surname><given-names>NJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><article-title>Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies</article-title><source>Bone Res</source><year>2018</year><volume>6</volume><fpage>15</fpage><pub-id pub-id-type="pmid">29736302</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_008"><label>[8]</label><element-citation publication-type="journal"><name><surname>Chou</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Ch</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><article-title>The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases</article-title><source>Biomark Insights</source><year>2007</year><volume>2</volume><fpage>165</fpage><comment>-</comment><lpage>171</lpage><pub-id pub-id-type="pmid">19662201</pub-id>
</element-citation></ref><ref id="j_rir-2023-0033_ref_009"><label>[9]</label><element-citation publication-type="journal"><name><surname>Atzeni</surname><given-names>F</given-names></name><name><surname>Talotta</surname><given-names>R</given-names></name><name><surname>Masala</surname><given-names>IF</given-names></name><name><surname>Bongiovanni</surname><given-names>S</given-names></name><name><surname>Boccassini</surname><given-names>L</given-names></name><name><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><article-title>Biomarkers in Rheumatoid Arthritis</article-title><source>Isr Med Assoc J</source><year>2017</year><volume>19</volume><fpage>512</fpage><comment>-</comment><lpage>516</lpage><pub-id pub-id-type="pmid">28825772</pub-id>
</element-citation></ref></ref-list></back></article>
